A cancer immunotherapy modality based on dendritic cell reprogramming in vivo
Ervin Ascic, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannová, Nadezhda Rotankova, Charlotte Veser, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, , Carlos‐Filipe Pereira
This study reprograms tumor cells in vivo to function as dendritic cells, leading to tumor regression and long-term immunity in mouse models.
Science · Aug 1, 2024Peer-reviewedImmunology